High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
The company said products are moving through its distribution network at or above normal levels as the Marlborough, Mass., company works to fulfill customer orders, reduce backlogs and accelerate the delivery of products.
Boston Scientific expects to provide updated full-year 2026 guidance along with its third-quarter results on Oct. 28, 2026.
Medical-device maker Boston Scientific said that it is unlikely to meet its sales growth and earnings expectations for the year, citing a major cyberattack disclosed last month that left it unable to fill orders.
On this episode of Stock Movers: - Novartis (NOVN) shares are lower as it suffered its third clinical-trial setback in a week after a treatment for a rare muscle-wasting disease failed a late-stage study. - Boston Scientific (BSX) shares are moving on news it said that fallout from a cybersecurity incident has impacted its ability to ship its products to customers and will cause the medical devices company to miss its sales growth and earnings estimates for the year. - Intel (INTC) is rising on a report that the company could raise computer chip prices next month.
Despite making progress restoring global operations, the device maker said in a securities filing that it is unlikely to meet third-quarter and full-year sales and earnings forecasts.
Boston Scientific (BSX) identified a cybersecurity incident affecting certain information technology
Boston Scientific said it likely won’t meet its financial guidance due to the cyberattack that has disrupted its operations, sending shares of the medical-technology company down sharply in premarket trading.
Boston Scientific said it likely won’t meet its financial guidance due to the cyberattack that has disrupted its operations, sending shares of the medical-technology company down sharply in premarket trading.
Sept 8 () - Boston Scientific said on Tuesday a cybersecurity incident that disrupted manufacturing and order shipments globally is likely to have a material impact on its third-quarter and full-year 2026 results. The medical device maker is unlikely to meet its previously issued third-quarter and full-year sales and adjusted profit forecast, it said in a regulatory filing.
Protolabs (PRLB) CEO and President Suresh Krishna joins Market Domination's Josh Lipton to discuss the Trump administration considering additional semiconductor tariffs and the American reshoring of manufacturing.
Alabama’s attorney general wants answers after OpenAI models went rogue during a test run and hacked a real-world company. The state this week subpoenaed OpenAI and CEO Sam Altman, looking for details about the incident as well as every employee involved, plus those who raised safety concerns. On Wednesday, the company released a lengthy report that addressed some, but not all, of the issues Alabama raised.
Aug 26 (Reuters) - Boston Scientific said on Wednesday that a cybersecurity incident had disrupted global operations, including some information systems used to process and ship customer orders.
WATCHMAN and Electrophysiology headwinds force guidance cut despite solid organic growth.
Boston Scientific (BSX) reported Q2 revenue and EPS that beat expectations but lowered its full-year
BSX faces WATCHMAN and EP pressures as management cuts outlook while highlighting cost savings and new product catalysts for future growth.
Moby summary of Boston Scientific Corporation's Q2 2026 earnings call
Boston Scientific (NYSE:BSX) reported second-quarter 2026 revenue growth at the high end of its guidance range and adjusted earnings per share above expectations, but lowered its full-year outlook as it faces slowing demand in its WATCHMAN left atrial appendage closure business and increased competi
Boston Scientific Corp (BSX) reports a robust Q2 with 7% organic sales growth and a 15% increase in adjusted EPS, despite challenges in some segments.
The medical device maker topped second-quarter expectations but now sees full-year adjusted EPS of $3.28 to $3.32, down from a prior range of $3.34 to $3.41
July 29 (Reuters) - Medical device maker Boston Scientific on Wednesday lowered its annual profit forecast, citing pressure on its Watchman heart device business.
Wall Street analysts are busy reshuffling their ratings ahead of the Fed meeting, with surprise double-upgrades, dramatic target cuts, and fresh initiations spanning surgical robots to cybersecurity. Find out which names made the biggest moves today.
Medical device company Boston Scientific (NYSE:BSX) will be reporting earnings this Wednesday morning. Here’s what to expect.
The trade tech company says Cervo AI can speed up customs brokerage tasks as tariff and trade policies shift.
Boston Scientific is gearing up for earnings day, weighing a rocky stock run against Wall Street's stubbornly optimistic outlook.
Sometimes boring stocks can be the most exciting.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
